- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07946107
BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (NOBLEHEART-HCM)
November 13, 2026 updated by: Braveheart Bio, Inc.
A Phase 3, Multi-region, Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of BHB-1893 in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
The main purpose of this trial is to find out whether BHB-1893 works better than placebo in adults with non-obstructive hypertrophic cardiomyopathy (nHCM).
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
600
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Study Director
- Phone Number: (415) 707-6312
- Email: clinicaltrials@braveheart.bio
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Diagnosed with HCM per protocol-defined criteria
- NYHA Class II or III at screening visits
- KCCQ-CSS that meets the protocol-specified criteria at screening visits
- Adequate acoustic windows for echocardiography
Key Exclusion Criteria:
- Resting systolic blood pressure (SBP) of >160 millimeters of mercury (mmHg) at screening visits
- Resting heart rate of >100 beats per minute (bpm) at screening visits
- Significant valvular heart disease
Additional protocol-defined inclusion and exclusion criteria apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: BHB-1893
Participants will receive BHB-1893 twice daily. |
Tablets for oral use |
|
Placebo Comparator: Placebo
Participants will receive matching placebo twice daily. |
Tablets for oral use |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from Baseline in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)
Time Frame: Baseline, Week 36
|
Baseline, Week 36
|
|
Change from Baseline in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise (CPET)
Time Frame: Baseline, Week 36
|
Baseline, Week 36
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent Change from Baseline in N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) Concentration
Time Frame: Baseline, Week 36
|
Baseline, Week 36
|
|
Percent Change from Baseline in High-sensitivity Cardiac Troponin I (hsc-TnI) Concentration
Time Frame: Baseline, Week 36
|
Baseline, Week 36
|
|
Number of Participants with >=1 Class Improvement in New York Heart Association (NYHA) Class
Time Frame: Baseline to Week 36
|
Baseline to Week 36
|
|
Change from Baseline in Left Atrial Volume Index (LAVI)
Time Frame: Baseline, Week 36
|
Baseline, Week 36
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Study Director, Braveheart Bio, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
December 1, 2026
Primary Completion (Estimated)
December 1, 2029
Study Completion (Estimated)
January 1, 2030
Study Registration Dates
First Submitted
November 13, 2026
First Submitted That Met QC Criteria
November 13, 2026
First Posted (Actual)
November 18, 2026
Study Record Updates
Last Update Posted (Actual)
November 18, 2026
Last Update Submitted That Met QC Criteria
November 13, 2026
Last Verified
November 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BHB-1893-302
- 2026-527471-29-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.